Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Top approved MS therapies in the U.S. by ARR 2014

Selected approved multiple sclerosis therapies as of 2014, ranked by ARR*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until Oct 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

July 2014

Region

United States

Survey time period

2014

Supplementary notes

* ARR = annualized relapse rate.
** For mitoxantrone, the primary outcome measure for efficacy in the progressive types of MS was a composite of five elements: Expanded Disability Status Scale (EDSS) scores, Ambulation Index, number of relapses requiring treatment with steroids, months to first relapse needing treatment with steroids, and Standard Neurological Status. Data in the table for mitoxantrone have been extracted from the study; however, these were not the primary outcome measures.
***ARR for Tecfidera ranges from 44 to 53.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical industry in the United Kingdom (UK)"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.